Good MorningEquity markets reversed two days of losses to advance to a new high on Wednesday following better-than-expected economic data. Investors cheered hot ISM services and Factory Orders data suggesting both aspects of the US economy are regaining momentum. If true, investors should also expect another uptick in inflation as demand puts added pressure on the economy.
In other news, oil prices continue to slide and fall below key support at the $96 level following a slight increase in production from OPEC. This move may trigger additional selling, but the worse news is the implication for the economy. Oil prices are not expected to contract without a major slow down in activity, and we've yet to see one. In this light, the decline in oil prices is either a precursor to a deeper economic recession or a whipsaw move and buying opportunity. Featured: The Coin That Could Define Trump’s Crypto Presidency (Ad) 
|
Stocks | | |
Typically when a mature company’s share price is hovering around $20 or below, it means that growth prospects are limited. But that’s not always the case.
As we’ve seen during this year’s market downturn, even well-run, fundamentally sound companies can get dragged down wi... Read the Full Story |
|
From Our Partners | | Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II.
They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | | Watch the National Emergency broadcast here |
|
Politics | | | Stocks on Wall Street closed broadly higher Wednesday as investors welcomed encouraging economic data and quarterly earnings reports from big companies including Starbucks.
The S&P 500 rose 1.6% to an almost 2-month high, while the Nasdaq gained 2.6%. Both indexes more than recoup... Read the Full Story |
|
Politics | | | Stocks on Wall Street are extending their gains in afternoon trading Wednesday as investors review a mostly encouraging batch of quarterly earnings from several big companies.
The S&P 500 rose 1.7% as of 3:02 p.m. Eastern. The Dow Jones Industrial Average rose 453 points, or 1.4%,... Read the Full Story |
|
From Our Partners | | The End of Elon Musk? Don't make him laugh.
Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again.
And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again.
According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | | Click here to see why the "End of Elon" crowd is about to be wrong again. |
|
Stocks | | |
Devon Energy (NYSE:DVN) may be an overlooked company in the oil and gas sector. However, that may change after the company releases earnings this week. The $5.63 billion in revenue beat expectations by 18%. And on the bottom line, the news was equally impressive, with the company posting $2.59 ear... Read the Full Story |
|
Stocks | | |
The health care sector is just barely participating in the S&P 500’s nascent rally, but pharmaceuticals such as AbbVie (NYSE:ABBV), Merck (NYSE:MRK) and Pfizer (NYSE:PFE) are holding up well relative to the broader market.
All three reported earnings recently, and while none got a... Read the Full Story |
|
From Our Partners | |
On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the fallout. Whether Powell hikes or cuts, both paths lead to wealth destruction for unprepared investors.
American Alternative Assets just released the Mar-A-Lago Accord, revealing how elites are positioning ahead of the decision—and how you can do the same.
| | Click here to get the free guide and protect your savings before the Fed acts. |
|
Stocks | | |
Media entertainment company Warner Brothers Discovery (NYSE: WBD) stock has languished since its spin-off as it fell to new all-time lows at $12.77 and down (-41%) year-to-date. Formerly Discovery Networks, the merging with WarnerMedia has created a content powerhouse including popular brands like... Read the Full Story |
|
Markets | | |
The entire energy infrastructure complex is moving higher and Energy Transfer LP (NYSE: ET) may lead the bunch. The company’s diversified approach to energy and its reliance on fee-based income make it stand out from other energy companies and its own peers. Trading at 7.33X its earnings it ... Read the Full Story |
|
Tech | | | Toyota’s profit fell nearly 18% in the April-June quarter from the year before, as a semiconductor shortage that has slammed the auto industry dented production at Japan’s top automaker.
Toyota Motor Corp. reported Thursday a quarterly profit of 736.8 billion yen ($5.5 billion), down... Read the Full Story |
|
Politics | | | President Joe Biden traveled to Saudi Arabia last month on the possibility that he could get some additional oil production out of OPEC+ in coming weeks, but the cartel and other nations announced a scant increase Wednesday.
The White House responded by stressing that what matters is ... Read the Full Story |
|
Politics | | | President Joe Biden traveled to Saudi Arabia last month on the possibility that he could get some additional oil production out of OPEC+ in coming weeks — but the cartel and other nations announced a scant increase on Wednesday.
The White House responded by stressing that what matters... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada. | | View Today's Stock Pick |
|
